Par Drugs And Chemicals Limited has informed the Exchange regarding 'Outcome of Board Meeting 08.05.2025'.
PAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board approved audited standalone financial results for Q4 and FY25 with an unmodified audit opinion from Sarupria Somani & Associates. FY25 revenue from operations grew about 5.6% year-on-year to Rs. 10,097.35 lakhs, but net profit declined roughly 7.9% to Rs. 1,335.79 lakhs, pushing EPS down to Rs. 10.86 from Rs. 11.78. Q4 standalone net profit came in at Rs. 165.10 lakhs on revenue of Rs. 2,232.99 lakhs. The company paid Rs. 23.79 lakh as 10% bonus to employees for FY25, has zero borrowings, and held cash plus investments of about Rs. 5,265 lakhs. The auditor flagged a key audit matter on going concern, noting the board had approved a slump sale of the company's primary business unit that contributed over 99% of revenue, and that the company plans to enter clean energy, real estate, and capital markets segments.
Mixed short-term results: top-line growth but higher expenses dragged profit lower. The bigger story is the strategic exit from the core API business that generated nearly all revenue, with a pivot planned toward clean energy, real estate, and capital markets - a major business model change that creates near-term uncertainty for shareholders but could also unlock value from the cash pile.